Genomics firm Integrated DNA Technologies (IDT) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx in vitro diagnostic (IVD) offerings, marking its first move into clinical diagnostics.
The strategic move into the next generation sequencing (NGS) IVD market, aims to reinforcing IDT’s commitment to quality, regulatory compliance, and clinical impact. By introducing IVD-grade solutions in the US and select European countries, IDT is filling a market gap for standardised workflows in oncology diagnostics.
“At IDT, we believe that precision diagnostics should be as reliable as they are innovative,” said Ajay Gannerkote, President, IDT. “This launch reflects our commitment to supporting clinical laboratories with trusted solutions that combine innovative technology, ease-of-use, and regulatory assurance, so clinicians can focus on their mission-critical work to find the right answers across the expanding biomarker landscape.”
The launch of Archer IVD assay solutions signals a leap forward in access to innovative IDT technologies that accelerate the path toward accurate, actionable insight for diagnostic laboratories. VARIANTPlex-HT Dx and FUSIONPlex-HT Dx (pictured above) are built on IDT’s proprietary Anchored Multiplex PCR (AMP) chemistry for targeted DNA- and RNA-sequencing with ease of use and efficiency front of mind. Each kit includes color-coded, technician- and robot-friendly reagents, adapters, and magnetic cleanup beads. In addition, the workflow steps can run in parallel, enabling efficient, simple library preparation.
IDT is sharpening its NGS strategy by expanding its capabilities through IVD in direct response to growing market demand in the clinical space. By expanding product offerings and introducing IVD-grade reagents, IDT is addressing a critical need among molecular pathology laboratories for workflows that ensure accuracy, consistency, and a seamless transition from discovery to diagnostics. With evolving regulatory requirements in the US and Europe, this new product introduction creates critical continuity to support laboratories as they navigate increasing complex biomarker landscapes with high confidence in both routine and high-stakes clinical settings.
IDT will continue to expand on its Archer IVD solutions portfolio with future planned launches based on the foundational, easy-to-use anchored multiplex-PCR technology with the ultimate goal of open access to the full range of Archer NGS assay capabilities including novel fusion and complex variant detection for challenging sample types.
For more information, and to order Archer IVD products, visit www.idtdna.com/ArcherIVD.